Welcome to our dedicated page for RELMADA THERAPEUTICS SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics (RLMD) Q2-25 10-Q snapshot: The company remains pre-revenue and reported a Q2 net loss of $9.9 m (-44% YoY) and a 6-month loss of $27.4 m (-31% YoY) after sharply reducing R&D spend following the wind-down of its REL-1017 and psilocybin programs. Operating expenses fell 46% YoY to $10.2 m for the quarter.
Balance-sheet pressure intensified. Cash & cash equivalents dropped to $1.35 m (vs. $3.86 m YE-24) while short-term investments fell to $19.3 m (vs. $41.1 m), leaving $20.6 m of liquid resources. With $24.5 m operating cash burn in H1 and no revenue, management warns of substantial doubt about going-concern status.
Key corporate actions:
- Acquired Phase-2b-ready Sepranolone for €3 m cash.
- Licensed NDV-01 (Phase 2 NMIBC) for $3.5 m cash plus 3.0 m shares (≈10% dilution) and up to $200 m milestones; early Phase 2 data show 90% 6-month CR.
- Terminated esmethadone and psilocybin programs to focus resources on the new assets.
- Received Nasdaq bid-price deficiency notice; listing transferred to Nasdaq Capital Market with cure period to 19 Jan 2026.
Capital structure: Shares outstanding rose to 33.2 m (vs. 30.2 m YE-24); options outstanding 14.2 m; warrants 0.75 m. No ATM sales to date. Equity now stands at $15.9 m (vs. $35.5 m).
Outlook: Management is evaluating financing alternatives and may scale trial activity; upcoming catalysts include 9- and 12-month NDV-01 Phase 2 read-outs (2H-25) and planned IND for US trials in 1H-26.
Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.